One in two Europeans believe biotechnology will improve quality of life

52% of those polled in the latest Eurobarometer survey on biotechnology, published today, indicated a belief that biotechnology will improve their quality of life. The Eurobarometer "Europeans and biotechnology in 2005" shows that most Europeans are in favour of medical (red) applications of biotechnology when there are clear benefits for human health; and industrial (white) applications, but they are still mostly sceptical about agricultural (green) biotech, and will continue to be so unless new crops and products are seen to have consumer benefits. Confidence has increased in the European Union's regulation of biotechnology but there is no evidence that this has influenced the public's reported purchasing intentions, especially for GM foods. Overall, optimism about biotechnology's contribution to improving society has grown significantly since 1999. There is also support for research using stem cells, provided this is tightly regulated. This survey is the latest in a series of regular surveys on attitudes to biotechnology undertaken since 1991.

The survey examines issues such as:

  • Optimism about the contribution of technology , including biotechnology, to our way of life. Here, the survey shows that optimism about biotechnology has increased since 1999, after a period of decline (52% say it will improve their life).
  • The development of nanotechnology, pharmacogenetics (analysing a person’s genetic code in order to create drugs which are tailored to him/her and are therefore more effective) and gene therapy, all three of which are generally perceived as useful to society and morally acceptable.
  • GM food , where a majority of Europeans (58%) think it should not be encouraged.
  • Industrial (white) biotechnologies, such as bio-fuels, bio-plastics (plastics manufactures from crop plants) and biopharming (the use of genetically modified plants in the production of medicines and pharmaceutical products) for pharmaceuticals, which are widely supported.
  • Stem cell research , where there is considerable support across Europe, if tightly regulated. There is approval for use of both stem cells derived from umbilical cords (65%) and embryonic stem cells (59%), with 26% of people saying they do not approve of embryonic stem cell research at all or only under very special circumstances.
  • Use of personal genetic data , with 58% of participants indicating they would allow their genetic data to be banked for research purposes, though there are differing levels of support for genetic data banks across the EU.
  • Trust in actors involved in biotechnology , which shows growing levels of trust in university and industry scientists (73% and 64%). The EU is seen as more trustworthy than national governments on issues of regulating biotechnology (74% compared with 68%).
  • Comparison of attitudes with US and Canada , dispelling claims that European public opinion is more technology-adverse than its transatlantic partners. Close analysis of the data shows that it is inaccurate to ascribe certain attitudes to biotechnology by age group, or gender.

This survey is the latest in a series of such Eurobarometers on biotechnology conducted in 1991, 1993, 1996, 1999, 2002 and 2005. The sixth Eurobarometer on Biotechnology 2005 is based on a representative sample of 25 000 respondents, approximately 1 000 in each EU Member State.

The experts who undertook this survey will present the findings at a workshop on 22 June. To download the full report and read the executive summary, please visit: www.ec.europa.eu/research/press/2006/pr1906en.cfm

Most Popular Now

ChatGPT Extracts Data for Ischaemic Stro…

In an ischaemic stroke, an artery in the brain is blocked by blood clots and the brain cells can no longer be supplied with blood as a result. Doctors must...

Herefordshire and Worcestershire Health …

Herefordshire and Worcestershire Health and Care NHS Trust has successfully implemented Alcidion's Miya Precision platform to streamline bed management workflow across seven community hospitals in Worcestershire. The trust delivers community...

A Shortcut for Drug Discovery

For most human proteins, there are no small molecules known to bind them chemically (so called "ligands"). Ligands frequently represent important starting points for drug development but this knowledge gap...

New Horizon Europe Funding Boosts Europe…

The European Commission has announced the launch of new Horizon Europe calls, with a substantial funding pool of over €112 million. These calls are aimed primarily at pioneering projects in...

Cleveland Clinic Study Finds AI can Deve…

Cleveland Clinic researchers developed an artficial intelligence (AI) model that can determine the best combination and timeline to use when prescribing drugs to treat a bacterial infection, based solely on...

New AI-Technology Estimates Brain Age Us…

As people age, their brains do, too. But if a brain ages prematurely, there is potential for age-related diseases such as mild-cognitive impairment, dementia, or Parkinson's disease. If "brain age...

With Huge Patient Dataset, AI Accurately…

Scientists have designed a new artificial intelligence (AI) model that emulates randomized clinical trials at determining the treatment options most effective at preventing stroke in people with heart disease. The model...

Radboud University Medical Center and Ph…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Radboud University Medical Center have signed a hospital-wide, long-term strategic partnership that delivers the latest patient monitoring...

GPT-4, Google Gemini Fall Short in Breas…

Use of publicly available large language models (LLMs) resulted in changes in breast imaging reports classification that could have a negative effect on patient management, according to a new international...

ChatGPT fails at heart risk assessment

Despite ChatGPT's reported ability to pass medical exams, new research indicates it would be unwise to rely on it for some health assessments, such as whether a patient with chest...

Study Shows ChatGPT Failed when Challeng…

With artificial intelligence (AI) poised to become a fundamental part of clinical research and decision making, many still question the accuracy of ChatGPT, a sophisticated AI language model, to support...

Virtual Reality Shows Promise in Fightin…

A new study published in JMIR Mental Health sheds light on the promising role of virtual reality (VR) in treating major depressive disorder (MDD). Titled "Examining the Efficacy of Extended...